{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shimizu A"],"funding":["The Japan Agency for Medical Research and Development"],"pagination":["498-506"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12950100"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(3)"],"pubmed_abstract":["Background
Although proteinuria is a key prognostic marker in immunoglobulin A nephropathy (IgAN), the optimal post-biopsy timing for its assessment remains uncertain, particularly given variability in treatment type and timing. Using longitudinal data from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS), we sought to identify the post-biopsy time point at which proteinuria most reliably predicts kidney outcomes.Methods
Proteinuria was assessed at baseline and at 6, 12, 18, and 24 months after biopsy. The primary outcome was defined as a ≥ 50% increase in serum creatinine or initiation of kidney replacement therapy in adults (≥ 20 years) and as a ≥ 25% decline in eGFR or initiation of kidney replacement therapy in patients aged < 20 years. Model performance was"],"journal":["Clinical and experimental nephrology"],"pubmed_title":["Post-biopsy proteinuria as a universal prognostic marker across diverse clinical courses in IgA nephropathy."],"pmcid":["PMC12950100"],"funding_grant_id":["JP19ek0109261"],"pubmed_authors":["Tomino Y","Miura K","Ito T","Kikuchi M","Yokoo T","Honma S","Joh K","J-IGACS working group","Miyazaki Y","Sasaki T","Ichikawa D","Kawamura T","Katafuchi R","Hashiguchi A","Suzuki H","Shirai S","Shibata T","Shimizu A","Suzuki Y","Yasuda T","Takahashi K","Ueda H","Nishikawa M","Nakatani S","Yasuda Y","Hataya H","Aoki R","Fujimoto S","Hirano K","Sanada S","Matsuzaki K","Muta K","Fukao Y","Nihei Y","Okabe M","Moriyama T","Nakanishi K","Fukuda A","Sakaguchi R","Shima Y","Kihara M","Tsuboi N","Yokote S","Nishino T","Koike K","Urushihara M"],"additional_accession":[]},"is_claimable":false,"name":"Post-biopsy proteinuria as a universal prognostic marker across diverse clinical courses in IgA nephropathy.","description":"Background
Although proteinuria is a key prognostic marker in immunoglobulin A nephropathy (IgAN), the optimal post-biopsy timing for its assessment remains uncertain, particularly given variability in treatment type and timing. Using longitudinal data from the Japan IgA Nephropathy Prospective Cohort Study (J-IGACS), we sought to identify the post-biopsy time point at which proteinuria most reliably predicts kidney outcomes.Methods
Proteinuria was assessed at baseline and at 6, 12, 18, and 24 months after biopsy. The primary outcome was defined as a ≥ 50% increase in serum creatinine or initiation of kidney replacement therapy in adults (≥ 20 years) and as a ≥ 25% decline in eGFR or initiation of kidney replacement therapy in patients aged < 20 years. Model performance was","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-17T01:11:02.124Z","creation":"2026-07-12T03:13:07.69Z"},"accession":"S-EPMC12950100","cross_references":{"pubmed":["41636940"],"doi":["10.1007/s10157-025-02808-3"]}}